Elizabeth H Aylward1, Deborah L Harrington2, James A Mills3, Peggy C Nopoulos3, Christopher A Ross4, Jeffrey D Long3, Dawei Liu3, Holly K Westervelt5, Jane S Paulsen6. 1. Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA. 2. Department of Radiology, University of California, San Diego, La Jolla, CA, USA VA San Diego Healthcare System, Research Service, San Diego, CA, USA. 3. Department of Psychiatry, The University of Iowa Carver College of Medicine, Iowa City, IA, USA. 4. Departments of Psychiatry, Neurology and Neuroscience, Johns Hopkins University, Baltimore, MD, USA. 5. Division of Biology and Medicine, Department of Psychiatry and Human Behavior, Brown University, Providence, RI, USA. 6. Departments of Psychiatry, Neurology, Psychology and Neuroscience, The University of Iowa Carver College of Medicine, Iowa City, IA, USA.
Abstract
BACKGROUND: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). OBJECTIVE: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. METHODS: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. RESULTS: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. CONCLUSIONS: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.
BACKGROUND: Neuroimaging studies suggest that volumetric MRI measures of specific brain structures may serve as excellent biomarkers in future clinical trials of Huntington disease (HD). OBJECTIVE: Demonstration of the clinical significance of these measures is an important step in determining their appropriateness as potential outcome measures. METHODS: Measures of gray- and white-matter lobular volumes and subcortical volumes (caudate, putamen, globus pallidus, thalamus, nucleus accumbens, hippocampus) were obtained from MRI scans of 516 individuals who tested positive for the HD gene expansion, but were not yet exhibiting signs or symptoms severe enough to warrant diagnosis ("pre-HD"). MRI volumes (corrected for intracranial volume) were correlated with cognitive, motor, psychiatric, and functional measures known to be sensitive to subtle changes in pre-HD. RESULTS: Caudate, putamen, and globus pallidus volumes consistently correlated with cognitive and motor, but not psychiatric or functional measures in pre-HD. Volumes of white matter, nucleus accumbens, and thalamus, but not cortical gray matter, also correlated with some of the motor and cognitive measures. CONCLUSIONS: Results of regression analyses suggest that volumes of basal ganglia structures contributed more highly to the prediction of most motor and cognitive variables than volumes of other brain regions. These results support the use of volumetric measures, especially of the basal ganglia, as outcome measures in future clinical trials in pre-HD. Results may also assist investigators in selecting the most appropriate measures for treatment trials that target specific clinical features or regions of neuropathology.
Entities:
Keywords:
Huntington disease; cognitive; magnetic resonance imaging; motor; psychiatric
Authors: Jane S Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K Williams; Sheila Simpson; Douglas Langbehn; Daniel P van Kammen Journal: Mov Disord Date: 2010-11-15 Impact factor: 10.338
Authors: Leigh J Beglinger; Justin J F O'Rourke; Chiachi Wang; Douglas R Langbehn; Kevin Duff; Jane S Paulsen Journal: Psychiatry Res Date: 2010-05-15 Impact factor: 3.222
Authors: Jane S Paulsen; Peggy C Nopoulos; Elizabeth Aylward; Christopher A Ross; Hans Johnson; Vincent A Magnotta; Andrew Juhl; Ronald K Pierson; James Mills; Douglas Langbehn; Martha Nance Journal: Brain Res Bull Date: 2010-04-10 Impact factor: 4.077
Authors: Peggy C Nopoulos; Elizabeth H Aylward; Christopher A Ross; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Ronald K Pierson; James Mills; Douglas R Langbehn; Jane S Paulsen Journal: Neurobiol Dis Date: 2010-08-02 Impact factor: 5.996
Authors: K Duff; J Paulsen; J Mills; L J Beglinger; D J Moser; M M Smith; D Langbehn; J Stout; S Queller; D L Harrington Journal: Neurology Date: 2010-07-07 Impact factor: 9.910
Authors: N Z Hobbs; J Barnes; C Frost; S M D Henley; E J Wild; K Macdonald; R A Barker; R I Scahill; N C Fox; S J Tabrizi Journal: AJNR Am J Neuroradiol Date: 2010-02-11 Impact factor: 3.825
Authors: Kelly C Rowe; Jane S Paulsen; Douglas R Langbehn; Kevin Duff; Leigh J Beglinger; Chiachi Wang; Justin J F O'Rourke; Julie C Stout; David J Moser Journal: Neuropsychology Date: 2010-07 Impact factor: 3.295
Authors: Ronald Pierson; Hans Johnson; Gregory Harris; Helen Keefe; Jane S Paulsen; Nancy C Andreasen; Vincent A Magnotta Journal: Neuroimage Date: 2010-06-25 Impact factor: 6.556
Authors: Caroline K Jurgens; Reineke Bos; Jasper Luyendijk; Marie-Noëlle W Witjes-Ané; Jeroen van der Grond; Huub A M Middelkoop; Raymund A C Roos Journal: J Neurol Date: 2009-10-13 Impact factor: 4.849
Authors: P Conforti; D Besusso; V D Bocchi; A Faedo; E Cesana; G Rossetti; V Ranzani; C N Svendsen; L M Thompson; M Toselli; G Biella; M Pagani; E Cattaneo Journal: Proc Natl Acad Sci U S A Date: 2018-01-08 Impact factor: 11.205
Authors: Katherine L Possin; Hosung Kim; Michael D Geschwind; Tacie Moskowitz; Erica T Johnson; Sharon J Sha; Alexandra Apple; Duan Xu; Bruce L Miller; Steven Finkbeiner; Christopher P Hess; Joel H Kramer Journal: Neuropsychologia Date: 2017-04-17 Impact factor: 3.139
Authors: Karen A Nunley; Christopher M Ryan; Howard J Aizenstein; J Richard Jennings; Rebecca L MacCloud; Trevor J Orchard; Caterina Rosano Journal: Psychosom Med Date: 2017-06 Impact factor: 4.312
Authors: Qian Ma; Jianmin Yang; Teresa A Milner; Jean-Paul G Vonsattel; Mary Ellen Palko; Lino Tessarollo; Barbara L Hempstead Journal: JCI Insight Date: 2017-05-04
Authors: Eduardo E Arteaga-Bracho; Maria Gulinello; Michael L Winchester; Nandini Pichamoorthy; Jenna R Petronglo; Alicia D Zambrano; Julio Inocencio; Chirstopher D De Jesus; Joseph O Louie; Solen Gokhan; Mark F Mehler; Aldrin E Molero Journal: Neurobiol Dis Date: 2016-09-10 Impact factor: 5.996